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Simple Summary: Marking impalpable areas of breast cancer prior to surgery is an important part of
the modern treatment of breast cancer. Traditionally, the target lesion would be marked by a wire just
before surgery under image guidance and would help the surgeon locate the tumour during surgery.
However, this method has some drawbacks, such as patient discomfort, the risk of migration and
dislodgement, and the need to couple surgical and radiological schedules. Therefore, there has been
a growing interest in this system, thus supporting its potential. In this study, we have evaluated one
such system, SAVI SCOUT®, in 63 consecutive patients. Our experience with this system supported
its potential role in modern breast surgery.
Abstract: Wire-guided localisation (WGL) has been the mainstay for localising non-palpable breast
lesions before excision. Due to its limitations, various wireless alternatives have been developed.
In this prospective study, we evaluate the role of radiation-free wireless localisation using the
SAVI SCOUT® system at the London Breast Institute. A total of 72 reflectors were deployed in
67 consecutive patients undergoing breast conserving surgery for non-palpable breast lesions. The
mean interval between deployment and surgery for the therapeutic cases was 18.8 days (range:
0–210). The median deployment duration was 5 min (range: 1–15 min). The mean distance from
the lesion was 1.1 mm (median distance: 0; range: 0–20 mm). The rate of surgical localisation and
retrieval of the reflector was 98.6% and 100%, respectively. The median operating time was 28 min
(range: 15–55 min) for the therapeutic excision of malignancy and 17 min (range: 15–24) for diagnostic
excision. The incidence of reflector migration was 0%. Radial margin positivity in malignant cases
was 7%. The median weight for malignant lesions was 19.6 g (range: 3.5–70 g). Radiologists and
surgeons rated the system higher than WGL (93.7% and 98.6%, respectively; 60/64 and 70/71). The
patient mean satisfaction score was 9.7/10 (n = 47, median = 10; range: 7–10). One instance of signal
failure was reported. In patients who had breast MRI after the deployment of the reflector, the MRI
void signal was <5 mm (n = 6). There was no specific technique-related surgical complication. Our
study demonstrates that wire-free localisation using SAVI SCOUT® is an effective and time-efficient
alternative to WGL with excellent physician and patient acceptance.
Keywords: breast cancer; localisation; occult; SAVI SCOUT®; non-palpable breast lesions; reflector-
guided localisation
1. Introduction
Non-palpable breast lesions form a large portion of treated breast lesions. Breast
conserving surgery (BCS) has been the dominant paradigm in the surgical treatment of
breast neoplastic lesions for the last four decades. Especially in non-palpable lesions, some
form of pre-operative localisation of the lesion is often crucial to BCS [1]. The earliest
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modality for localising impalpable lesion was wire-guided localisation (WGL), which has
remained the mainstay for localising non-palpable breast lesions before excision [2,3].
However, WGL does have its drawbacks. It is uncomfortable for the patient and carries
a minor risk of needle-stick injury to the surgeon. The wire cannot be retained for prolonged
periods. Therefore, slots for radiological insertion of the wire need to be coordinated within
24 h of the resectional surgery. This poses a significant strain on ongoing services, as well
as an impediment to the establishment of new services. Wires could migrate or fracture,
making it difficult to identify the lesion marked for excision [4–6]. Diathermy burns may
occur during surgery as heat or current could be conducted to the skin surface [7]. Due to
these and other limitations, various alternatives have been developed in search of more
optimal methods of non-palpable breast lesion localisation without the limitations of WGL.
The earliest attempts involved the use of radioactive 125I seeds implanted under radi-
ological guidance [8,9]. However, the use radioactive seed localisation (RSL) comes with a
significant regulatory burden inherent to the use of radioactive materials, which doubtlessly
has dissuaded its wider adoption [10,11]. This has encouraged the development of novel
non-radioactive, wire-free localisation methods. Examples of devices currently available in-
clude LOCalizer™ (Hologic Inc., Santa Carla CA, USA), which makes use of radiofrequency
identification tags (RFID) [12]; Magseed® (Endomag limited, Cambridge, UK), which uses
a ferro-magnetic tracer to direct a hand-held magnetometer [13], and SAVI SCOUT® (Merit
Medical, Aliso Viejo, CA, USA), which utilises a proprietary electromagnetic wave reflector
(Figure 1) [14].
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Figure 1. The SAVI SCCOUT® reflector (12 mm long, deployable by a 16 GA needle), with a coin 
for comparison. 
In the SAVI SCOUT® localisation system, the reflector can be inserted within or near 
the targeted breast tissue lesion using a bespoke delivery system. This can be conducted 
under ultrasound or mammogram guidance in the radiology suite. The reflector can later 
be localised during surgery by an infra-red emitting detector system which provides a 
distance to target reading (Figure 2). Successful extraction of the reflector can be con-
firmed during surgery using the detector or specimen radiographs. The reflector can also 
be used to mark axillary lymph nodes for targeted dissection and has been approved by 
the FDA for implantation for an unlimited pre-operative period [15]. 
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2. Materials and Methods
2.1. Setting
T is technique was evaluated in a prospective cohort of 67 patients undergoing thera-
peutic excision of non-palpable breast cancer (n = 57; median age = 53; range: 27–81 years),
or diagnostic excision of screen-detected indeterminate/benign breast abnormality (n = 10:
median age = 45.5; range: 28–69 years). Of the 57 patients undergoing therapeutic excision,
44 pr sented with screen-detected malignancy and 13 had non-palpable tumours after
neoadjuvant chemotherapy. All patients had triple assessment, including imaging-guided
core biopsy, prior to surgery.
This study was performed at the London Breast Institute within the Princess Grace
Hospital (London, UK). Patients who required the excision of non-palpable breast lesions
were recruited and decisions regarding treatment were made following discussion within
the multidisciplinary team.
The radiologist and surgeons of this centre involved in this study have had years
of experience with the standard WGL techniques. Furthermore, both LOCalizer™ and
Magseed® were evaluated recently for use in our practice [16].
This is a prospective observational clinical evaluation. Therefore, formal ethical ap-
proval was deemed unnecessary. However, the use of these technologies was approved
by the institution’s multidisciplinary breast cancer board as well as the clinical gover-
nance team of the Princess Grace Hospital. All participants signed an informed written
consent and detailed patient information leaflets regarding this novel wireless technique
were provided.
The primary end points were: 1. rate of successful localisation and retrieval; 2. fre-
quency of positive radial surgical margins for malignant lesions requiring surgical re-
excision. Surgical margins were considered positive if the tumour was less than 1 mm away
from the nearest radial margin for invasive cancer and 2 mm for pure ductal carcinoma in
situ (DCIS); 3. complications specifically related to the SAVI SCOUT® system.
All patients had a control normal mammography film following deployment (Figure 3)
and specimen mammography (Figure 4) following surgical excision. These images were
used to evaluate the reflector distance from the lesion and migration.
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Figure 4. Breast resection specimen with SAVI SCOUT® reflector (R) and marker clip (M) adjacent to
the tumour. Peripheral metallic clips can also be seen (i, m and s) for orientation.
2.2. Data Collection
Data were also c llect 1. duration of radi logical deployment of r -
flector; 2. distance between reflector and target lesion; 3. duration of surgical procedure;
4. incidence of migration of reflector; 5. patient and physician acceptance; 6. weight of
surgical specimen.
3. Results
SAVI SCOUT® reflectors (n = 72) (Figure 4) were deployed under ultrasound (n = 66)
or stereotactic X-ray guidance (n = 5) in 67 consecutive patients including 57 patients
presenting with non-palpable breast malignancy at the time of diagnosis (n = 44) or after
neoadjuvant chemotherapy (n = 13) up to 210 days prior to surgery (Tables 1 and 2).
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Table 2. Pathological characteristics and localisation details in diagnostic cases.
Case Age




















1 58 0 1 18 7.5 much better 10 Papilloma 0
2 47 0 4 19 11.5 much better 10 Benign breastchange 0
0 4 19 13.5 Papilloma





4 68 0 3 16 - much better ADH 0
5 48 0 5 15 7.5 neutral CSL
6 28 0 5 15 3 better Fibroadenoma 0
7 34 1 (stereotactic) 5 24 11 - LCIS/ALH/CSL 0
8 36 1 5 17 5 better papilloma 0
9 38 0 4 16 8 better Atypical columnarchange 3
10 44 0 5 17 18 better 10 CSL 0
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The mean interval between deployment and surgery for the therapeutic cases was
18.8 days (range: 0–210).
A total of 72 reflectors were deployed in 67 patients (five patients had two reflectors).
The nearest distance between the reflectors was 17 mm.
The median deployment duration was 5 min (range: 1–15 min), with a mean distance
from the breast lesion of 1.1 mm and a median distance of 0 (range: 0–20 mm).
The rate of successful surgical localisation and retrieval of the reflector was 98.6% and
100%, respectively.
The median operating time including identification and retrieval was 28 min (range:
15–55 min) for therapeutic excision and 17 min (range: 15–24) for diagnostic excision.
A total of six patients had breast MRI after the deployment of the reflector and the
MRI void signal was smaller than 5 mm in all cases (Figure 5).
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Figure 5. Breast MRI demonstrating a good partial response to NST for TNBC. It demonstrates a
small (4.6 mm) MRI void signal generated by the SAVI SCOUT® reflector located within the residual
tumour (in the upper inner quadrant of the right breast) that decreased.
The pathological tumour size ranged from 0 (ypT0) to 67 mm (T3). In patients un-
dergoing therapeutic excision for malignancy (n = 57), four (7%) required reoperation for
positive radial surgical margins. In all four cases, preoperative imaging underestimated
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the tumour size by more than 100% and three out of four patients had no residual disease
in the re-excision specimens. The median weight for malignant lesions was 19.6 g (range:
3.5–70 g).
3.1. Radiologists’ and Surgeon’s Acceptance
Radiologists’ responses were available for 64 procedures. Radiologists rated the SAVI
SCOUT® system as much better/better than WGL in 93.7% (60/64) of cases. The surgeon
involved rated the technique as better/much better in 98.6% (70/71) of cases.
The SAVI SCOUT® system was also preferred to Magseed® and LOCalizer™ by
radiologists (n = 6) and the breast surgeon. The mean radiologists rating was 8 (range: 7–9)
for SAVI SCOUT®, 7 (range: 6–8) for Magseed® and 5.2 (range: 4–6) for LOCalizer™. The
surgeon’s rating was 8, 7 and 6, respectively, with 5 being equal to wire-guided localisation.
3.2. Patients’ Acceptance
Patients’ feedback was obtained from 43 (64%) patients and the mean satisfaction
score was 9.7 out of 10 (median = 10; range: 7–10).
Post-operative pain scores were obtained from a pilot group of 13 patients (mean = 2.8/10;
range: 0–6).
3.3. Retrieval and Migration
The migration rate, defined as movement of SAVI SCOUT® reflector after deployment
by more than 5 mm, was 0%.
Although all SAVI SCOUT® reflectors were retrieved and the target lesion was re-
moved (100%), the signal could not be detected in the operating room in one case. It was
superficially placed and was located by palpation. The deactivation of the superficially
located SAVI SCOUT® reflector by the surgical lights system was considered as a possible
cause of this failure (Figure 3).
3.4. Complications
There were no specific SAVI SCOUT®-related surgical complications.
There was one patient who developed a hematoma that required evacuation and
another patient developed a minor wound dehiscence that was sutured under local anaes-
thesia in the outpatient setting.
4. Discussion
As stated earlier, the localisation of occult lesions within the breast is crucial for much
of BCS. This is predominantly achieved by WGL, which has been in mode since its initial
description in the 1970s and remains the current standard of care [2,17].
The significant limitations of WGL highlighted above have stimulated interest in
developing alternatives that overcome the aforementioned limitations.
An early alternative was radio-labelled seed localisation (RSL). In this technique, a
titanium seed containing 125I is implanted at the site of the lesion and is located intra-
operatively with a gamma camera. This had shown considerable promise with regard to
patient acceptability, learning curve, and accuracy in the form of low margin positivity [18].
Furthermore, as the seed could be retained safely for up to 5 days, the scheduling require-
ments were less onerous with RSL compared to WGL [10]. However, the expense and
regulatory burden associated with the use of radioactive agents are important practical
considerations [19]. Whilst exceedingly unlikely, fracturing of retained radio-labelled seeds
during histopathological slicing has been reported in the literature, and would have to
be accounted for in workplace guidelines and procedures [6]. Together, these limitations
probably dissuade the wide-spread adoption of RSL.
In recent years, there have been several developments of wireless non-radioactive
localisation techniques for breast lesions. An obvious advantage of such modalities would
be the possibility of leaving the marker in situ for longer periods of time, easing pressures
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on the scheduling of the procedures. However, the devices available are proprietary and
are currently being evaluated in different jurisdictions [20]. Some use ferro-magnetic seeds
or solutions as tracers coupled with a handheld magnetometer, such as Magseed® and
MaMaLoc (Sirius Medical, Eindhoven, the Netherlands) [13,21]. Another wire-free system,
LOCalizerTM, uses radiofrequency identification tags [22].
SAVI SCOUT® uses an electromagnetic wave reflector which reflects a combination of
infra-red and radar signals from a handheld detector. It has been approved by the FDA for
long-term implantation [15].
Our study provides further evidence supporting the reliability of the SAVI SCOUT®
system in guiding breast conserving surgery and confirms the benefits of the technology in
advancing patient care. Our findings by and large coincide with the findings of Srour et al.,
with no observed device-specific complications, migration of device, and favourable de-
ployment and retrieval rates and durations [23]. We observed a margin positivity rate of 7%,
which is significantly lower than the 22% re-excision rate observed in the UK NHS Breast
Screening Programme [24]. However, our series included, in addition to screen-detected
cancers, 11 patients who received neoadjuvant systemic therapy (NST) to downstage
the disease.
Preoperative imaging underestimated the tumour size by more than 100% in all four
cases with positive margin. This suggests that the margin positivity rate we observed may
be unrelated to the localisation technique used. In addition, our recently conducted pooled
analysis reported a pooled analysis overall re-excision rate of 12.9% for SAVI SCOUT®
versus 21% for WGL (relative risk = 0.61) in studies comparing the two methods [25].
When taken in context with the relatively low specimen weight (19.5 g), the low
rate of margin positivity is evidence of the accuracy of SAVI SCOUT® as a localisation
modality compared to WGL. This aspect, as well as issues pertaining to learning curves
and inter-operator variability, would be a worthy subject of future investigations.
Within our current study cohort, the median duration for reflector deployment was
found to be 5 min, half the time reported for wire placement during WGL (10 min) [17]. Our
study also found that reflectors were placed at the target tissue site at a mean interval of
15.3 days before surgery. Srour et al. compared SAVI SCOUT® with WGL across a range of
time-specific variables [23]. Their results showed that WGL is associated with significantly
longer delays in surgical operation starting times, as well as longer preoperative times
on the day of surgery. These findings vindicate the raison d’etre for the novel wire-free
localisation systems, such as SAVI SCOUT®, allowing for the decoupling of radiology
and surgical scheduling, potentially resulting in more efficient use of healthcare facilities,
labour and capital.
Our study enables us to compare our experience with this technology to the other
radiation-free wireless localisation systems for non-palpable breast lesions. A recent
systematic review and pooled analysis conducted by our institute [26] found the Magseed®
localisation system to have similarly high successful placement (94.42%) and retrieval rates
(99.86%) as the SAVI SCOUT® system (99.64% and 99.64%, respectively) [25]. However,
the margin positivity rate observed in our study is significantly lower than that reported
by a similar institution using Magseed® (24%), despite a similar median specimen weight
of 19.5 g [27].
Several other more qualitative advantages of the SAVI SCOUT® system over Magseed®
localisation are also evident. The SAVI SCOUT® detector console gives the distance from
the reflector, which is a glaring omission in the case of the Magseed® system. Magseeds®
can only be detected up to a depth of 4 cm from the skin surface whilst the SAVI SCOUT®
reflector is recommended for use up to 6 cm depths [28]. This allows for the localisation
of deeper lesions, resulting in greater usability of the technology. Furthermore, we have
found that the device did not interfere with MRI scans in any significant way. This is in line
with previous studies, which have reported minimal MRI signal interferences by the SAVI
SCOUT® reflector, measuring <5 mm [29]. In contrast, RFID tags and Magseeds® have been
associated with significant MRI signal void artefacts, which may impede the monitoring
Cancers 2021, 13, 2409 12 of 15
and identification of residual disease on follow-up MRI scans [29]. Furthermore, the SAVI
SCOUT® reflector could be deployed at the time of biopsy in patients undergoing NST as
it would not interfere in the monitoring of disease response to treatment by imaging. This
could save patients a second procedure and enable the more efficient utilisation of hospital
resources. The SAVI SCOUT® reflector is also more easily visualised on ultrasonography
than magnetic seeds or RFID tags.
When compared to LOCalizer™, SAVI SCOUT® has a few salient advantages. Com-
pared to SAVI SCOUT®, LOCalizer™ has a much larger MRI void artefact compared to
SAVI SCOUT® (20 mm vs. 5 mm), which limits LOCalizer™’s utility in the neoadjuvant set-
ting. SAVI SCOUT® has a smaller introducer compared to LOCalizer™ (16 gauge compared
to 12), which may have an effect on patient acceptance and deployment accuracy [20].
Importantly, SAVI SCOUT® was associated with a high degree of patient satisfaction.
This is likely due to several factors, including the ability to deploy the reflector at diagnostic
biopsy, the lack of time delays on the day of surgery and the minimal discomfort associated
with deployment.
Radiologists and surgeons preferred SAVI SCOUT® to WGL, as well as other novel
localisation technologies which were recently in use at our institution (LOCalizerTM and
Magseed®). It was preferred to Magseed® in view of the need to remove all metal surgical
tools from the surgical field when the attempting to localise the Magseed® using the
detection probe [5]. The other influencing factor was the significant MRI void signals
associated with Magseed® biopsy in patients considered for NST [26].
The SAVI SCOUT® localisation system has also been approved for use in targeted
axillary lymph node dissection (TAD) (Figure 6). Although published data are limited,
several existing studies have reported the successful use of the reflector system to localise
axillary lymph nodes [30–32]. Sun et al. reported the successful retrieval of all SAVI
SCOUT® reflectors with no intra- or postoperative complications [32]. The successful
deployment of SAVI SCOUT® to mark and excise lymph nodes with minimal MRI signal
interference suggest that the SAVI SCOUT® system is an effective technology for use in
TAD following NST.
We observed only one instance of signal loss. Interestingly, it was in a device inserted
closer to the skin than usual (Figure 3). This is in contrast to the literature, which reports
that the signal is more likely to fail at depths greater than 4 cm [33]. We believe this
signal failure may have been due to overhead theatre lights interfering with the device
and we therefore initially recommend that the reflector is deployed behind the lesion for
superficially located masses. However, further research into this is required.
Several other limitations of the SAVI SCOUT® system warrant mention. Although
rare, the reflector cannot be used in patients who are allergic to nickel, somewhat limiting
its use. Furthermore, initial research reported that the deactivation of the reflector may
occur when it encounters surgical electrocautery. However, the manufacturer has since
made modifications to overcome this limitation [15]. In addition, antenna transection has
been reported during surgical dissection, again potentially resulting in signal loss [34]. In
either scenario, the signal loss is unlikely to pose an issue to the operating surgeon as the
reflector would be in close proximity and could be palpated easily. Calcified fibroadenomas
and post-biopsy haematoma have been described as causing issues with signal detection
within the operating theatre [31,35]. Previous research has suggested that this may be
overcome by placing the reflector next to the haematoma, rather than within the mass [31].
As a prospective cohort study, we believe our data provide good evidence for strongly
considering SAVI SCOUT® as an alternative to WGL in the management of occult breast
lesions. Ours is the first study evaluating this system in Europe. We believe this technology
should be further evaluated in comparison to other novel localisation systems as well as
WGL and RSL, in order to better establish its non-inferiority to current gold standards.
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The limitations of our study include a relatively small sample size (67 reflectors).
However, our findings contribute to the growing body of the literature and are consistent
with our recently published pooled analysis of 842 reflectors [25]. Furthermore, this study
was conducted in an academic facility, and involved a senior academic breast surgeon and
several dedicated breast radiologists. These findings may not be universally generalisable
and should be replicated in more representative tertiary care centres.
More ver, we did not perform a direct he d-to-head comparison with WGL, Magseeds®
or LOCaliz rTM. Prosp ctive studies i l i t se modalities w uld be essential to in-
form best practice.
The benefits in ter s of the decoupling of surgical and radiological timeslots and
reduced patient discomfort should mo than offset the costs in the medium term. This
is indeed a issue which has not thus far been adequately addressed [26]. Good quality
evidenc pertaining to this issue would have an appreciable ffect on the quality of care we
could offer to breast cancer patients in the future.
5. Conclusions
Our study demonstrates th wire-fr e loc lisation using SAVI SCOUT® s a viabl
and promising alternative to WGL with excellent physician and patient accept nce.
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